Dragonfly and Celgene Extended their Collaboration from 2017, for the Treatment of Solid and Hematological Cancers

 Dragonfly and Celgene Extended their Collaboration from 2017, for the Treatment of Solid and Hematological Cancers

Dragonfly and Celgene Extended their Collaboration from 2017, for the Treatment of Solid and Hematological Cancers

Shots:

  • Celgene has added four more immunotherapies (making it eight, to 2017 deal) to develop and commercialize with an option to license WW IPR of the developed product, using Dragonfly’s TriNKET technology
  • Dragonfly to get $50M upfront with milestones and royalties (if the option to license is exercised by Celgene)
  • TriNKET technology (Tri-specific, NK cell Engager Therapeutics) uses NK cells, for developing immunotherapies for cancer

Click here to read full press release/ article | Ref: PRNewsWire| Image:  The Street

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post